Skip to main content
SpringerLink
Log in

Cancer Risk Associated with Subfertility and Ovulation Induction: A Review

  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Objective: Over the past decades the use of fertility drugs (FDs) has greatly increased. Recently, the possible association between the use of FDs and risk of cancer has aroused great concern. In this paper, we critically review the available epidemiologic studies.

Methods: We identified papers published between 1966 and 1999 that examined FDs and specific causes of subfertility in relation to the risks of cancers of the ovary, breast, endometrium and thyroid, and melanoma.

Results: Although present insights into the pathogenesis of hormone-related malignancies suggest a possible association between the use of FDs and the risk of specific cancers, this has not been convincingly demonstrated in epidemiologic studies. With regard to cancer risk in relation to the cause of subfertility, the only consistent association observed is an increased risk of endometrial cancer for women with subfertility due to hormonal disorders. While positive findings in some studies on FDs and ovarian cancer risk have aroused serious concern, the associations observed in most of these reports appear to be due to bias or chance rather than being causal. The most important sources of bias are inadequate confounder control for both parity and causes of subfertility.

Conclusions: To discriminate between the possible carcinogenic effects of various ovulation induction regimens, subfertility disorders, and reproductive characteristics associated with subfertility, future studies should include large populations of subfertile women with sufficient follow-up time. In such cohort studies the cause of subfertility should be measured adequately (based on medical records) and information about reproductive characteristics should be collected for all cohort members. Such studies should also include a group of subfertile women with an indication for FD use but not so treated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chandra A, Stephen EH (1998) Impaired fecundity in the United States: 1982–1995. Fam Plann Perspect 30: 34–42.

    Google Scholar 

  2. Beurskens MP, Maas JW, Evers JL (1995) Subfertility in South Limburg: calculation of incidence and appeal for specialist care. [Dutch]. Ned Tijdschr Geneeskd 139: 235–238.

    Google Scholar 

  3. Wysowski DK (1993) Use of fertility drugs in the United States, 1973 through 1991. Fertil Steril 60: 1096–1098.

    Google Scholar 

  4. Merkus JMWM (1991) Meerlingen en artificiele voortplanting (Abstract). Symposium: Meerlingen; de epidemie van de jaren negentig in de obstetrie.

  5. de Jong-van den Berg LTW, Cornel MC, van den Berg PB, et al. (1992) Ovulation-inducing drugs: a drug utilization and risk study in the Dutch population. Int J Risk Safety Med 3: 99–112.

    Google Scholar 

  6. Shu XO, Brinton LA, Gao YT, Yuan JM (1989) Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 49: 3670–3674.

    Google Scholar 

  7. Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136: 1184–1203.

    Google Scholar 

  8. Franceschi S, La Vecchia C, Negri E, et al. (1994) Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod 9: 1673–1675.

    Google Scholar 

  9. Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG (1996) Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 65: 13–18.

    Google Scholar 

  10. Parazzini F, Negri E, La Vecchia C, Moroni S, Franceschi S, Crosignani PG (1997) Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum Reprod 12: 2159–2161.

    Google Scholar 

  11. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN (1997) Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 67: 1005–1012.

    Google Scholar 

  12. Ron E, Lunenfeld B, Menczer J, et al. (1987) Cancer incidence in a cohort of infertile women. Am J Epidemiol 125: 780–790.

    Google Scholar 

  13. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG (1994) Ovarian tumors in a cohort of infertile women. N Engl J Med 331: 771–776.

    Google Scholar 

  14. Venn A, Watson L, Lumley J, Giles G, King C, Healy D (1995) Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 346: 995–1000.

    Google Scholar 

  15. Modan B, Ron E, Lerner-Geva L, et al. (1998) Cancer incidence in a cohort of infertile women. Am J Epidemiol 147: 1038–1042.

    Google Scholar 

  16. Harris R, Whittemore AS, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136: 1204–1211.

    Google Scholar 

  17. Parazzini F, Negri E, La Vecchia C, et al. (1998) Treatment for fertility and risk of ovarian tumors of borderline malignancy. Gynecol Oncol 68: 226–228.

    Google Scholar 

  18. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG (1996) Risk of breast cancer in a cohort in infertile women. Gynecol Oncol 60: 3–7.

    Google Scholar 

  19. Braga C, Negri E, La Vecchia C, Parazzini F, Dal Maso L, Franceschi S (1996) Fertility treatment and risk of breast cancer. Hum Reprod 11: 300–303.

    Google Scholar 

  20. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A (1999) Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 71: 853–859.

    Google Scholar 

  21. Venn A, Watson L, Bruinsma F, Giles G, Healy D (1999) Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 354: 1586–1590.

    Google Scholar 

  22. Bernstein L, Ross RK, Henderson BE (1992) Relationship of hormone use to cancer risk. J Natl Cancer Inst Monogr 12: 137–147.

    Google Scholar 

  23. Schildkraut JM, Schwingl PJ, Bastos E, Evano. A, Hughes C (1996) Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 88: 554–559.

    Google Scholar 

  24. Brinton LA, Melton LJ, Malkasian GD Jr, Bond A, Hoover R (1989) Cancer risk after evaluation for infertility. Am J Epidemiol 129: 712–722.

    Google Scholar 

  25. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG (1995) Risk of cutaneous melanoma in a cohort of infertile women. Melanoma Res 5: 123–127.

    Google Scholar 

  26. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A (1997) Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 176: 572–579.

    Google Scholar 

  27. Rodriguez C, Tatham LM, Calle EE, Thun MJ, Jacobs EJ, Heath CW Jr (1998) Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes Control 9: 645–651.

    Google Scholar 

  28. Le MG, Bachelot A, Hill C (1989) Characteristics of reproductive life and risk of breast cancer in a case-control study of young nulliparous women. J Clin Epidemiol 42: 1227–1233.

    Google Scholar 

  29. Gammon MD, Thompson WD (1990) Infertility and breast cancer: a population-based case-control study. Am J Epidemiol 132: 708–716.

    Google Scholar 

  30. Moseson M, Koenig KL, Shore RE, Pasternack BS (1993) The influence of medical conditions associated with hormones on the risk of breast cancer. Int J Epidemiol 22: 1000–1009.

    Google Scholar 

  31. Cowan LD, Gordis L, Tonascia JA, Jones GS (1981) Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 114: 209–217.

    Google Scholar 

  32. Coulam CB, Annegers JF, Kranz JS (1983) Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 61: 403–407.

    Google Scholar 

  33. Garland M, Hunter DJ, Colditz GA, et al. (1998) Menstrual cycle characteristics and history of ovulatory infertility in relation to breast cancer risk in a large cohort of US women. Am J Epidemiol 147: 636–643.

    Google Scholar 

  34. Escobedo LG, Lee NC, Peterson HB, Wingo PA (1991) Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women. Obstet Gynecol 77: 124–128.

    Google Scholar 

  35. Riman T, Persson I, Nilsson S (1998) Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol 49: 695–707.

    Google Scholar 

  36. Artini PG, Fasciani A, Cela V, et al. (1997) Fertility drugs and ovarian cancer. Gynecol Endocrinol 11: 59–68.

    Google Scholar 

  37. Tarlatzis BC, Grimbizis G, Bontis J, Mantalenakis S (1995) Ovarian stimulation and ovarian tumours: a critical reappraisal. Hum Reprod Update 1: 284–301.

    Google Scholar 

  38. Beltsos AN, Odem RR (1996) Ovulation induction and ovarian malignancy. Semin Reprod Endocrinol 14: 367–374.

    Google Scholar 

  39. Kaufman SC, Spirtas R, Alexander NJ (1995) Do fertility drugs cause ovarian tumors? J Women Health 4: 247–259.

    Google Scholar 

  40. Bristow RE, Karlan BY (1996) The risk of ovarian cancer after treatment for infertility. Curr Opin Obstet Gynecol 8: 32–37.

    Google Scholar 

  41. Burger CW, Kenemans P, Schoemaker J (1996) Ovarian hyper-stimulation: a risk factor for granulosa cell tumour of the ovary? CME J Gynecol Oncol 132–135.

  42. Bristow RE, Karlan BY (1996) Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 66: 499–507.

    Google Scholar 

  43. Lely C, Burger CW (1996) Fertility drugs and in vitro fertilisation and the risk of ovarian cancer. Oncol Pract 3: 12–14.

    Google Scholar 

  44. Shoham Z (1994) Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today? Fertil Steril 62: 433–448.

    Google Scholar 

  45. Mosgaard BJ, Lidegaard O, Andersen AN (1997) The impact of parity, infertility and treatment with fertility drugs on the risk of ovarian cancer. A survey. Acta Obstet Gynecol Scand 76: 89–95.

    Google Scholar 

  46. Nugent D, Salha O (1998) Ovarian neoplasia and subfertility treatments. Br J Obstet Gynaecol 105: 584–591.

    Google Scholar 

  47. Duckitt K, Templeton AA (1998) Cancer in women with infertility. Curr Opin Obstet Gynecol 10: 199–203.

    Google Scholar 

  48. Glud E, Kjaer SK, Troisi R, Brinton LA (1999) Fertility drugs and ovarian cancer. Epidemiol Rev 20: 237–257.

    Google Scholar 

  49. Heineman MJ (1996) Groeiend inzicht. Utrecht (NL): Wet-enschappelijke Uitgeverij Bunge.

    Google Scholar 

  50. Glasier AF (1990) Clomiphene citrate. BaillieÁres Clin Obstet Gynaecol 4: 491–501.

    Google Scholar 

  51. Clark JH, Markaverich BM (1981) The agonistic-antagonistic properties of clomiphene: a review. Pharmacol Ther 15: 467–519.

    Google Scholar 

  52. Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ (1986) Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril 46: 392–396.

    Google Scholar 

  53. Derman SG, Adashi EY (1994) Adverse effects of fertility drugs. Drug Saf 11: 408–421.

    Google Scholar 

  54. Brown JB (1978) Pituitary control of ovarian function-concepts derived from gonadotrophin therapy. Aust NZ J Obstetynaecol 18: 46–54.

    Google Scholar 

  55. Baird DT (1987) A model for follicular selection and ovulation: lessons from superovulation. J Steroid Biochem 27: 15–23.

    Google Scholar 

  56. Fishel S, Jackson P (1989) Follicular stimulation for high tech pregnancies: are we playing it safe? BMJ 299: 309–311.

    Google Scholar 

  57. March CM (1993) Ovulation induction. J Reprod Med 38: 335–346.

    Google Scholar 

  58. Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer statistics, 1998. CA Cancer J Clin 48: 6–29.

    Google Scholar 

  59. Ries LAG, Kosary CL, Hankey BF, Miller BA, Edwards BK (1998) SEER Cancer Statistics Review, 1973–1995. Bethesda, MD: National Cancer Institute.

  60. Adami HO, Bergstrom R, Persson I, Sparen P (1990) The incidence of ovarian cancer in Sweden, 1960–1984. Am J Epidemiol 132: 446–452.

    Google Scholar 

  61. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (1997) Cancer Incidence in Five Continents, Vol. VII. Lyon: IARC Scientific Publication No. 143.

  62. Doyle P, dos Santos Silva I (1996) Pathogenesis and epidemiol-ogy of ovarian cancer. In: Shingleton HM, Fowler WCJ, Jordan JA, Lawrence WD, eds. Gynecologic Oncology. Current Diagnosis and Treatment. London: WB Saunders, pp. 165–173.

    Google Scholar 

  63. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development (1987) The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 316: 650–655.

    Google Scholar 

  64. Negri E, Franceschi S, Tzonou A, et al. (1991) Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 49: 50–56.

    Google Scholar 

  65. Fathalla MF (1971) Incessant ovulation a factor in ovarian neoplasia? Lancet 2: 163.

    Google Scholar 

  66. Adami HO, Hsieh CC, Lambe M, et al. (1994) Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344: 1250–1254.

    Google Scholar 

  67. Albrektsen G, Heuch I, Kvale G (1996) Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study. Cancer Causes Control 7: 421–427.

    Google Scholar 

  68. Stadel BV (1975) Letter: The etiology and prevention of ovarian cancer. Am J Obstet Gynecol 123: 772–774.

    Google Scholar 

  69. Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71: 717–721.

    Google Scholar 

  70. Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and proges terone. J Natl Cancer Inst 90: 1774–1786.

    Google Scholar 

  71. Lux-Lantos VA, Thyssen SM, Chamson A, Libertun C (1995) E.ect of a gonadotropin releasing hormone analog on an experimental ovarian tumor: direct and indirect actions. Life Sci 57: 291–300.

    Google Scholar 

  72. Blaakaer J, Baeksted M, Micic S, Albrectsen P, Rygaard J, Bock J (1995) Gonadotropin-releasing hormone agonist suppres-sion of ovarian tumorigenesis in mice of the Wx/Wv genotype. Biol Reprod 53: 775–779.

    Google Scholar 

  73. McGowan L, Davis RH (1970) Intrasplenic ovarian grafts in Syrian hamsters and peritoneal fluid cellular distribution. Proc Soc Exp Biol Med 134: 507–509.

    Google Scholar 

  74. Rao AR (1981) Effects of carcinogen and/or mutagen on normal and gonadtotropin-primed ovaries of mice. Int J Cancer 28: 105–110.

    Google Scholar 

  75. Bengtsson M, Rydstrom J (1983) Regulation of carcinogen metabolism in the rat ovary by the estrous cycle and gonadotropin. Science 219: 1437–1438.

    Google Scholar 

  76. Simon WE, Holzel F (1979) Hormone sensitivity of gynecological tumor cells in tissue culture. J Cancer Res Clin Oncol 94: 307–323.

    Google Scholar 

  77. Simon WE, Albrecht M, Hansel M, Dietel M, Holzel F (1983) Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 70: 839–845.

    Google Scholar 

  78. Henderson BE, Ross R, Bernstein L (1988) Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 48: 246–253.

    Google Scholar 

  79. Cook LS, Kamb ML, Weiss NS (1997) Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol 145: 459–465.

    Google Scholar 

  80. Blejer HP, Arlon R (1973) Talc: a possible occupational and environmental carcinogen. J Occup Med 15: 92–97.

    Google Scholar 

  81. Graham J, Graham R (1967) Ovarian cancer and asbestos. Environ Res 1: 115–128.

    Google Scholar 

  82. Henderson WJ, Joslin CA, Turnbull AC, Griffiths K (1971) Talc and carcinoma of the ovary and cervix. J Obstet Gynaecol Br Commonw 78: 266–272.

    Google Scholar 

  83. Longo DL, Young RC (1979) Cosmetic talc and ovarian cancer. Lancet 2: 349–351.

    Google Scholar 

  84. Newhouse ML (1979) Cosmetic talc and ovarian cancer. Lancet 2: 528.

    Google Scholar 

  85. Parmley TH, Woodru. JD (1974) The ovarian mesothelioma. Am J Obstet Gynecol 120: 234–241.

    Google Scholar 

  86. Roe FJ (1979) Controversy: cosmetic talc and ovarian cancer. Lancet 2: 744.

    Google Scholar 

  87. Whittemore AS, Wu ML, Paffenbarger RS Jr, et al. (1988) Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol 128: 1228–1240.

    Google Scholar 

  88. Rosenblatt KA, Szklo M, Rosenshein NB (1992) Mineral fiber exposure and the development of ovarian cancer. Gynecol Oncol 45: 20–25.

    Google Scholar 

  89. Cramer DW, Welch WR, Scully RE, Wojciechowski CA (1982) Ovarian cancer and talc: a case-control study. Cancer 50: 372–376.

    Google Scholar 

  90. Hartge P, Hoover R, Lesher LP, McGowan L (1983) Talc and ovarian cancer. JAMA 250: 1844.

    Google Scholar 

  91. Booth M, Beral V, Smith P (1989) Risk factors for ovarian cancer: a case-control study. Br J Cancer 60: 592–598.

    Google Scholar 

  92. Harlow BL, Cramer DW, Bell DA, Welch WR (1992) Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol 80: 19–26.

    Google Scholar 

  93. Chen Y, Wu PC, Lang JH, Ge WJ, Hartge P, Brinton LA (1992) Risk factors for epithelial ovarian cancer in Beijing, China. Int J Epidemiol 21: 23–29.

    Google Scholar 

  94. Paulson RJ (1997) Fertility drugs and ovarian epithelial cancer: the endometriosis hypothesis. J Assist Reprod Genet 14: 228–230.

    Google Scholar 

  95. Hankinson SE, Hunter DJ, Colditz GA, et al. (1993) Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 270: 2813–2818.

    Google Scholar 

  96. Green A, Purdie D, Bain C, et al. (1997) Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer 71: 948–951.

    Google Scholar 

  97. Parazzini F, Negri E, La Vecchia C, Luchini L, Mezzopane R (1993) Hysterectomy, oophorectomy, and subsequent ovarian cancer risk. Obstet Gynecol 81: 363–366.

    Google Scholar 

  98. Irwin KL, Weiss NS, Lee NC, Peterson HB (1991) Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol 134: 362–369.

    Google Scholar 

  99. Sightler SE, Boike GM, Estape RE, Averette HE (1991) Ovarian cancer in women with prior hysterectomy: a 14–year experience at the University of Miami. Obstet Gynecol 78: 681–684.

    Google Scholar 

  100. Helzhouer KJ, Alberg AJ, Gordon GB, et al. (1995) Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 274: 1926–1930.

    Google Scholar 

  101. McGowan L, Parent L, Lednar W, Norris HJ (1979) The women at risk for developing ovarian cancer. Gynecol Oncol 7: 325–344.

    Google Scholar 

  102. Joly DJ, Lilienfeld AM, Diamond EL, Bross ID (1974) An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am J Epidemiol 99: 190–209.

    Google Scholar 

  103. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ (1983) Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 71: 711–716.

    Google Scholar 

  104. Hartge P, Schiffman MH, Hoover R, McGowan L, Lesher L, Norris HJ (1989) A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 161: 10–16.

    Google Scholar 

  105. Whittemore AS, Wu ML, Pa.enbarger RS Jr, et al. (1989) Epithelial ovarian cancer and the ability to conceive. Cancer Res 49: 4047–4052.

    Google Scholar 

  106. Risch HA, Weiss NS, Lyon JL, Daling JR, Li. JM (1983) Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 117: 128–139.

    Google Scholar 

  107. Risch HA, Marrett LD, Howe GR (1994) Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 140: 585–597.

    Google Scholar 

  108. John EM, Whittemore AS, Harris R, Itnyre J (1993) Characteristics relating to ovarian cancer risk: collaborative analysis of seven US case-control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group. J Natl Cancer Inst 85: 142–147.

    Google Scholar 

  109. Horn-Ross PL, Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. VI. Nonepithelial cancers among adults. Collaborative Ovarian Cancer Group. Epidemiology 3: 490–495.

    Google Scholar 

  110. Whittemore AS, Harris R, Itnyre J, Halpern J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Collaborative Ovarian Cancer Group. Am J Epidemiol 136: 1175–1183.

    Google Scholar 

  111. Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12UScase-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 136: 1212–1220.

    Google Scholar 

  112. Komatsu T, Konishi I, Mandai M, et al. (1995) Peritoneal papillary serous carcinoma arising in an infertile woman during ovulation-induction therapy: immunohistochemical expression of LH/hCG receptors. Gynecol Oncol 56: 470–474.

    Google Scholar 

  113. Bristow RE, Karlan BY (1997) Stage IV ovarian carcinoma following ovulation induction: a report of three cases. Int J Gynecol Cancer 7: 112–116.

    Google Scholar 

  114. Atlas M, Menczer J (1982) Massive hyperstimulation and borderline carcinoma of the ovary. A possible association. Acta Obstet Gynecol Scand 61: 261–263.

    Google Scholar 

  115. Bamford PN, Steele SJ (1982) Uterine and ovarian carcinoma in a patient receiving gonadotrophin therapy. Case report. Br J Obstet Gynaecol 89: 962–964.

    Google Scholar 

  116. Ben-Hur H, Dgani R, Lancet M, Katz Z, Nissim F, Rosenman D (1986) Ovarian carcinoma masquerading as ovarian hyperstimulation syndrome. Acta Obstet Gynecol Scand 65: 813–814.

    Google Scholar 

  117. Carter ME, Joyce DN (1987) Ovarian carcinoma in a patient hyperstimulated by gonadotropin therapy for in vitro fertilization: a case report. J In Vitro Fert Embryo Transf 4: 126–128.

    Google Scholar 

  118. Kulkarni R, McGarry JM (1989) Follicular stimulation and ovarian cancer. BMJ 299: 740.

    Google Scholar 

  119. Dietl J (1991) Ovulation and ovarian cancer. Lancet 338: 445.

    Google Scholar 

  120. Goldberg GL, Runowicz CD (1992) Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation is there a link? Am J Obstet Gynecol 166: 853–854.

    Google Scholar 

  121. Lopes P, Mensier A (1993) Ovarian cancer and assisted reproductive technology. Eur J Obstet Gynecol Reprod Biol 51: 171–173.

    Google Scholar 

  122. Balasch J, Barri PN (1993) Follicular stimulation and ovarian cancer? Hum Reprod 8: 990–996.

    Google Scholar 

  123. Karlan BY, Marrs R, Lagasse LD (1994) Advanced-stage ovarian carcinoma presenting during infertility evaluation. Am J Obstet Gynecol 171: 1377–1378.

    Google Scholar 

  124. Ismail SM, Walker SM (1990) Bilateral virilizing sclerosing stromal tumours of the ovary in a pregnant woman with Gorlin's syndrome: implications for pathogenesis of ovarian stromal neoplasms. Histopathology 17: 159–163.

    Google Scholar 

  125. Grimbizis G, Tarlatzis BC, Bontis J, et al. (1995) Two cases of ovarian tumours in women who had undergone multiple ovarian stimulation attempts. Hum Reprod 10: 520–523.

    Google Scholar 

  126. Bandera CA, Cramer DW, Friedman AJ, Sheets EE (1995) Fertility therapy in the setting of a history of invasive epithelial ovarian cancer. Gynecol Oncol 58: 116–119.

    Google Scholar 

  127. Nijman HW, Burger CW, Baak JP, Schats R, Vermorken JB, Kenemans P (1992) Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases. Eur J Cancer 28A: 1971–1973.

    Google Scholar 

  128. Willemsen W, Kruitwagen R, Bastiaans B, Hanselaar T, Rolland R (1993) Ovarian stimulation and granulosa-cell tumour. Lancet 341: 986–988.

    Google Scholar 

  129. Unkila-Kallio L, Leminen A, Tiitnen A, Lehtovirta P, Wahlstrom T, Ylikorkala O (1997) Malignant tumors of the ovary or the breast in association with infertility: a report of thirteen cases. Acta Obstet Gynecol Scand 76: 177–181.

    Google Scholar 

  130. Nasca PC, Greenwald P, Chorost S, Richart R, Caputo T (1984) An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol 119: 705–713.

    Google Scholar 

  131. Buitendijk SE, Verkerk PH, Verloove-Vanhorick SP (1993) Fertility enhancing drugs and ovarian carcinoma. [Dutch]. Ned Tijdschr Geneeskd 137: 1643–1644.

    Google Scholar 

  132. Spirtas R, Kaufman SC, Alexander NJ (1993) Fertility drugs and ovarian cancer: red alert or red herring? Fertil Steril 59: 291–293.

    Google Scholar 

  133. Cohen J, Forman R, Harlap S, et al. (1993) IFFS expert group report on the Whittemore study related to the risk of ovarian cancer associated with the use of infertility agents. Hum Reprod 8: 996–999.

    Google Scholar 

  134. Evers JL (1993) Fertility-promoting drugs and ovarian carcinoma. [Dutch]. Ned Tijdschr Geneeskd 137: 1993–1994.

    Google Scholar 

  135. Caro JJ, Johannes CB, Hartz SC, Marrs R, Miettinen OS (1993) Re: ``Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women''. Am J Epidemiol 137: 928–929.

    Google Scholar 

  136. Land JA (1993) Ovulation, ovulation induction and ovarian carcinoma. Baillieres Clin Obstet Gynaecol 7: 455–472.

    Google Scholar 

  137. Rossing MA, Daling JR, Weiss NS (1995) Risk of ovarian cancer after treatment for infertility. N Engl J Med 332: 1302.

    Google Scholar 

  138. Harlow BL, Weiss NS, Roth GJ, Chu J, Daling JR (1988) Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 48: 5849–5852.

    Google Scholar 

  139. Jansen R (1993) Ovarian stimulation and granulosa-cell tumour. Lancet 341: 1345.

    Google Scholar 

  140. Kelsey JL, Horn-Ross PL (1993) Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev 15: 7–16.

    Google Scholar 

  141. Kelsey JL, Bernstein L (1996) Epidemiology and prevention of breast cancer. Annu Rev Public Health 17: 47–67.

    Google Scholar 

  142. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713–1727.

    Google Scholar 

  143. Rookus MA, van Leeuwen FE (1994) Oral contraceptives and risk of breast cancer in women aged 20–54 years. Netherlands Oral Contraceptives and Breast Cancer Study Group. Lancet 344: 844–851.

    Google Scholar 

  144. Colditz GA, Hankinson SE, Hunter DJ, et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589–1593.

    Google Scholar 

  145. Beral V, Banks E, Reeves G, Wallis M (1997) Hormone replacement therapy and high incidence of breast cancer between mammographic screens. Lancet 349: 1103–1104.

    Google Scholar 

  146. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047–1059.

    Google Scholar 

  147. Key TJ, Pike MC (1988) The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24: 29–43.

    Google Scholar 

  148. Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC (1985) Do regular ovulatory cycles increase breast cancer risk? Cancer 56: 1206–1208.

    Google Scholar 

  149. Brzezinski A, Peretz T, Mor-Yosef S, Schenker JG (1994) Ovarian stimulation and breast cancer: is there a link? Gynecol Oncol 52: 292–295.

    Google Scholar 

  150. Bolton PM (1977) Bilateral breast cancer associated with clomiphene. Lancet 2: 1176.

    Google Scholar 

  151. Arbour L, Narod S, Glendon G, et al. (1994) In-vitro fertilisation and family history of breast cancer. Lancet 344: 610–611.

    Google Scholar 

  152. Laing RW, Glaser MG, Barrett GS (1989) A case of breast carcinoma in association with in vitro fertilization. J R Soc Med 82: 503.

    Google Scholar 

  153. Sutherland RL, Watts CK, Hall RE, Ruenitz PC (1987) Mechanisms of growth inhibition by nonsteroidal antioestro-gens in human breast cancer cells. J Steroid Biochem 27: 891–897.

    Google Scholar 

  154. Colditz GA, Rosner B (1998) Use of estrogen plus progestin is associated with greater increase in breast cancer than estrogen alone. Am J Epidemiol 147: (Abstract).

  155. Sta.a JA, Newscha.er CJ, Jones JK, Miller V (1992) Progestins and breast cancer: an epidemiologic review. Fertil Steril 57: 473–491.

    Google Scholar 

  156. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO (1994) Transient increase in the risk of breast cancer after giving birth. N Engl J Med 331: 5–9.

    Google Scholar 

  157. Kroman N, Wohlfahrt J, Andersen KW, Mouridsen HT, Westergaard T, Melbye M (1997) Time since childbirth and prognosis in primary breast cancer: population based study. BMJ 315: 851–855.

    Google Scholar 

  158. Kvale G, Heuch I, Nilssen S (1991) Reproductive factors and cancers of the breast and genital organs are the different cancer sites similarly affected? Cancer Detect Prev 15: 369–377.

    Google Scholar 

  159. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A (1983) The epidemiology of endometrial cancer in young women. Br J Cancer 47: 749–756.

    Google Scholar 

  160. Jensen H (1985) Endometrial carcinoma. A retrospective, epidemiological study. Dan Med Bull 32: 219–228.

    Google Scholar 

  161. Pettersson B, Adami HO, Bergstrom R, Johansson ED (1986) Menstruation span a time-limited risk factor for endometrial carcinoma. Acta Obstet Gynecol Scand 65: 247–255.

    Google Scholar 

  162. Parazzini F, La Vecchia C, Negri E, Fedele L, Balotta F (1991) Reproductive factors and risk of endometrial cancer. Am J Obstet Gynecol 164: 522–527.

    Google Scholar 

  163. Brinton LA, Berman ML, Mortel R, et al. (1992) Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 167: 1317–1325.

    Google Scholar 

  164. van Leeuwen FE, Rookus MA (1989) The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer. Eur J Cancer Clin Oncol 25: 1961–1972.

    Google Scholar 

  165. Brinton LA, Hoover RN (1993) Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 81: 265–271.

    Google Scholar 

  166. Jick SS, Walker AM, Jick H (1993) Estrogens, progesterone, and endometrial cancer. Epidemiology 4: 20–24.

    Google Scholar 

  167. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G (1991) Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 338: 274–277.

    Google Scholar 

  168. Beresford SA, Weiss NS, Voigt LF, McKnight B (1997) Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349: 458–461.

    Google Scholar 

  169. Weiss NS, Sayvetz TA (1980) Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 302: 551–554.

    Google Scholar 

  170. Kaufman DW, Shapiro S, Slone D, et al. (1980) Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med 303: 1045–1047.

    Google Scholar 

  171. Hulka BS, Chambless LE, Kaufman DG, Fowler WC Jr, Greenberg BG (1982) Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 247: 475–477.

    Google Scholar 

  172. The Centers for Disease Control Cancer and Steroid Hormone Study (1983) Oral contraceptive use and the risk of endometrial cancer. JAMA 249: 1600–1604.

    Google Scholar 

  173. Rosenblatt KA, Thomas DB (1991) Hormonal content of com-bined oral contraceptives in relation to the reduced risk of en-dometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 49: 870–874.

    Google Scholar 

  174. Key TJ (1995) Hormones and cancer in humans. Mutat Res 333: 59–67.

    Google Scholar 

  175. Key TJ, Pike MC (1988) The dose-effect relationship between ``unopposed'' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57: 205–212.

    Google Scholar 

  176. Dahlgren E, Friberg LG, Johansson S, et al. (1991) Endometrial carcinoma; ovarian dysfunction-a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 41: 143–150.

    Google Scholar 

  177. Elwood JM, Cole P, Rothman KJ, Kaplan SD (1977) Epidemiology of endometrial cancer. J Natl Cancer Inst 59: 1055–1060.

    Google Scholar 

  178. Kelsey JL, LiVolsi VA, Holford TR, et al. (1982) A case-control study of cancer of the endometrium. Am J Epidemiol 116: 333–342.

    Google Scholar 

  179. Wynder EL, Escher GC, Mantel N (1966) An epidemiological investigation of cancer of the endometrium. Cancer 19: 489–520.

    Google Scholar 

  180. Stadel BV (1976) Dietary iodine and risk of breast, endometrial, and ovarian cancer. Lancet 1: 890–891.

    Google Scholar 

  181. La Vecchia C, Franceschi S, Gallus G, et al. (1982) Oestrogens and obesity as risk factors for endometrial cancer in Italy. Int J Epidemiol 11: 120–126.

    Google Scholar 

  182. Holly EA, Cress RD, Ahn DK (1994) Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol Biomarkers Prev 3: 661–668.

    Google Scholar 

  183. Gallagher RP, Elwood JM, Hill GB, Coldman AJ, Threlfall WJ, Spinelli JJ (1985) Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada Melanoma Study. Br J Cancer 52: 901–907.

    Google Scholar 

  184. Green A, Bain C (1985) Hormonal factors and melanoma in women. Med J Aust 142: 446–448.

    Google Scholar 

  185. Holman CD, Armstrong BK, Heenan PJ (1984) Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. Br J Cancer 50: 673–680.

    Google Scholar 

  186. Beral V, Ramcharan S, Faris R (1977) Malignant melanoma and oral contraceptive use among women in California. Br J Cancer 36: 804–809.

    Google Scholar 

  187. Kuppens E, Bergman W, Welvaart K, Bruijn JA, Sche.er E (1992) Multiple primary melanomas in a patient with familial-type DNS during clomiphene-induced pregnancy. Melanoma Res 2: 71–74.

    Google Scholar 

  188. Ron E, Kleinerman RA, Boice JD Jr, LiVolsi VA, Flannery JT, Fraumeni JF Jr (1987) A population-based case-control study of thyroid cancer. J Natl Cancer Inst 79: 1–12.

    Google Scholar 

  189. Preston-Martin S, Bernstein L, Pike MC, Maldonado AA, Henderson BE (1987) Thyroid cancer among young women related to prior thyroid disease and pregnancy history. Br J Cancer 55: 191–195.

    Google Scholar 

  190. McTiernan AM, Weiss NS, Daling JR (1984) Incidence of thyroid cancer in women in relation to reproductive and hormonal factors. Am J Epidemiol 120: 423–435.

    Google Scholar 

  191. Galanti MR, Lambe M, Ekbom A, Sparen P, Pettersson B (1995) Parity and risk of thyroid cancer: a nested case-control study of a nationwide Swedish cohort. Cancer Causes Control 6: 37–44.

    Google Scholar 

  192. Christov K (1975) Thyroid cell proliferation in rats and induction of tumors by X-rays. Cancer Res 35: 1256–1262.

    Google Scholar 

  193. Chan V, Paraskevaides CA, Hale JF (1975) Assessment of thyroid function during pregnancy. Br J Obstet Gynaecol 82: 137–141.

    Google Scholar 

  194. Osathanondh R, Tulchinsky D, Chopra IJ (1976) Total and free thyroxine and triiodothyronine in normal and complicated pregnancy. J Clin Endocrinol Metab 42: 98–104.

    Google Scholar 

  195. Weeke J, Hansen AP (1975) Serumfitsh and serum t3 levels during normal menstrual cycles and during cycles on oral contraceptives. Acta Endocrinol 79: 431–438.

    Google Scholar 

  196. La Vecchia C, Ron E, Franceschi S, et al. (1999) A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control 10: 157–166.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands

    Helen Klip & Flora E. van Leeuwen

  2. Department of Obstetrics and Gynaecology, University Hospital Rotterdam, The Netherlands

    Curt W. Burger

  3. Department of Obstetrics and Gynaecology, Academic Hospital Free University, Amsterdam, The Netherlands

    Peter Kenemans

Authors
  1. Helen Klip
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Curt W. Burger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kenemans
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Flora E. van Leeuwen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klip, H., Burger, C.W., Kenemans, P. et al. Cancer Risk Associated with Subfertility and Ovulation Induction: A Review. Cancer Causes Control 11, 319–344 (2000). https://doi.org/10.1023/A:1008921211309

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008921211309

Search

Navigation